A 2023 meta-analysis (5 trials, 1 cohort study, >2000 participants) revealed that glucagon-like-peptide-1 receptor agonists (GLP-1RAs) such as liraglutide and semaglutide produced moderate reductions in depression scores versus control treatments, independent of weight loss [133]. Here, GLP1R is linked to depressive symptom measurement.